Precision Neuroscience Raises $250M Series D to Commercialize BCI

Precision Neuroscience has raised $250 million in a Series D round to commercialize its brain-computer interface platform, according to an announcement reported by citybiz.

The financing marks one of the larger capital commitments in the implantable neurotechnology sector and positions the company to move its cortical recording technology from clinical development toward commercial availability. The company did not disclose a valuation in the announcement.

Precision Neuroscience is developing an electrode array designed to sit on the surface of the brain — a minimally invasive approach that records neural activity from the cortex without penetrating brain tissue. The platform targets patients with severe neurological impairment, including paralysis, with the goal of restoring communication and motor function through decoded neural signals.

Unlike fully invasive depth electrodes, the company's thin-film array sits on the cortical surface, an approach comparable in placement to subdural ECoG grids used in epilepsy monitoring, though engineered as a chronic implant with substantially higher electrode density than conventional clinical grids. The intended application is not seizure localization but real-time decoding of cortical signals for external device control.

The Series D proceeds will fund commercialization efforts, including scaling manufacturing and advancing clinical pathways for the device. The company has previously tested its implant in human subjects, and the new capital supports the transition from investigational use toward regulatory clearance and market introduction.

For clinical neurophysiology teams, the arrival of commercial cortical surface interfaces signals a growing overlap between intraoperative and monitoring-unit practice and the emerging BCI field. Hospitals that already host epilepsy surgery programs with ECoG expertise — electrode placement, high-density cortical recording, signal integrity management — hold much of the procedural infrastructure these devices require.

The funding also intensifies competition in the implantable BCI space, where several companies are pursuing both surface and penetrating electrode architectures. Precision's surface-mounted design emphasizes safety and reversibility, since the array can be removed without damaging brain tissue — a feature the company has cited as central to its regulatory and clinical strategy.

Investor confidence at this scale reflects tightening clinical evidence requirements across the field: devices must demonstrate durable, high-bandwidth neural decoding in human patients, not bench performance, to win clearance and reimbursement.

The company has not announced a specific timeline for FDA clearance or first commercial implants. The next milestones to watch are regulatory submissions and the scale of pivotal human trials funded by this round.